An immune attack on the insulation around nerve fibres. One region — the MHC — carries by far the largest inherited effect, and everything else, including the variant here, is part of a long tail of small ones.
Multiple sclerosis is a disease of the central nervous system in which the immune system attacks myelin, the insulating sheath around nerve fibres. The damage disrupts signalling, which produces episodes of neurological disturbance — vision loss, weakness, numbness, imbalance — and, over years, accumulating disability in many patients.
MS runs in families more than chance explains, and studies of families confirmed early that variation within the major histocompatibility complex exerts the greatest individual effect on risk — the MHC being the region that determines what the immune system treats as foreign.
Everything else is a long tail. Genome-wide studies have added many further risk loci, each contributing modestly, and the picture is of a disease driven by many immune variants acting together rather than by any single gene.
rs2300747 is recorded near CD58 from a 2009 meta-analysis of genome-wide scans: 2,624 people with MS and 7,220 controls, with replication in 2,215 further patients and 2,116 controls. That study's own headline findings were new susceptibility loci at TNFRSF1A, IRF8 and CD6 — all immune genes, and one of them, TNFRSF1A, carrying both a common variant of modest effect (odds ratio 1.2) and a rarer coding variant with a stronger one (frequency 0.02, odds ratio 1.6).
CD58 is an immune adhesion molecule involved in how T cells are activated and regulated, which is the kind of place MS variants tend to be.
Whether you will develop MS, when, or how it will behave. Diagnosis is made from the pattern of neurological episodes, MRI findings and, often, examination of spinal fluid — using criteria designed to demonstrate that lesions are separated in space and in time. No genotype is part of that, and none predicts the course.
What has changed the disease is treatment: a range of disease-modifying therapies now reduce relapses and, started early, change the long-term trajectory. That is where the meaningful decisions are, and they are made from clinical and imaging findings.
New neurological symptoms lasting more than a day — particularly loss of vision in one eye, double vision, numbness spreading over hours, or weakness — deserve prompt assessment. Nothing on this page substitutes for that.
Architecture. Family studies established that genetic factors account for much of the increased frequency of MS in relatives of affected individuals, with the MHC exerting the largest single effect — the class II haplotype containing HLA-DRB1 being the long-established primary association. Beyond it, genome-wide studies have identified a large number of loci of modest effect, concentrated in genes with immune functions, consistent with a primary role for cell-mediated immune mechanisms.
The source study. The 2009 meta-analysis combined genome-wide scans totalling 2,624 subjects with MS and 7,220 controls, with replication in 2,215 patients and 2,116 controls, validating TNFRSF1A (combined P = 1.59 x 10-11), IRF8 (P = 3.73 x 10-9) and CD6 (P = 3.79 x 10-9). TNFRSF1A harbours two independent susceptibility alleles: rs1800693, common with an odds ratio of 1.2, and rs4149584, a non-synonymous variant at frequency 0.02 with an odds ratio of 1.6. The susceptibility allele near IRF8 was associated with higher expression of interferon-response genes in people with MS. rs2300747 near CD58 is recorded against this analysis.
Clinical position. Diagnosis follows the McDonald criteria: clinical episodes plus MRI evidence of lesions disseminated in space and time, supported where needed by cerebrospinal fluid oligoclonal bands. Management is disease-modifying therapy selected by disease activity and risk tolerance, alongside symptomatic and rehabilitative care. Genotype has no role in diagnosis, prognosis or treatment selection; HLA associations are research and epidemiological tools.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Multiple Sclerosis comes down to these specific, well-studied positions — not a diagnosis.
No. Even the MHC — by far the largest inherited effect — is carried by many people who never develop MS. Diagnosis is made from neurological episodes, MRI and spinal fluid, never from a genotype.
Because that is what the disease is. The variants cluster in genes regulating T cells and interferon signalling, which is the strongest available argument that MS is driven by cell-mediated immunity rather than by something primarily neurological.
Both are part of the environmental picture that genetics does not explain: the disease is more common further from the equator, and EBV infection is now regarded as necessary though far from sufficient. Neither is settled enough to act on beyond ordinary health advice.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.